Disease Domain | Count |
---|---|
Neoplasms | 9 |
Top 5 Drug Type | Count |
---|---|
Monoclonal antibody | 3 |
Small molecule drug | 3 |
Antibody drug conjugate (ADC) | 2 |
Immune cell therapy | 1 |
Therapeutic radiopharmaceuticals | 1 |
Target |
Mechanism menin inhibitors |
Active Org. MorphImmune, Inc.Startup |
Originator Org. MorphImmune, Inc.Startup |
Active Indication |
Inactive Indication- |
Drug Highest PhaseEarly Phase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism IL-38 antagonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org. MorphImmune, Inc.Startup |
Originator Org. MorphImmune, Inc.Startup |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date03 Jun 2022 |
Sponsor / Collaborator Immunome, Inc. [+1] |
Start Date30 Mar 2021 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Mi-003 ( menin ) | Solid tumor More | Phase 1 Clinical |
IMM-20059 ( EPN1 ) | Neoplasms More | Preclinical |
Mi-002 | Scleroderma, Systemic More | Preclinical |
Mi-001(MorphImmune) ( TLR7 ) | Idiopathic Pulmonary Fibrosis More | Preclinical |
Mi-004 | - | Preclinical |